ARID1A and metastatic malignant neoplasm in the lymph nodes: Survival analysis demonstrated significantly reduced median DFS in ARID1A-low subgroup (29 months, 95%CI 27.33-NA) compared to ARID1A-high subgroup (NA, 95%CI 47-NA; P = 0.003) (Figure 8A).Univariate Cox modeling revealed four adverse prognostic factors: ARID1A deficiency (HR = 2.615, 95%CI 1.341-5.097, P = 0.005), an ECOG-PS of 2 (HR = 2.856, 95%CI 1.079-7.562, P = 0.035), Stage III (HR = 3.764, 95%CI 1.135-12.484, P = 0.030), and N2 lymph node metastasis (HR = 2.859, 95%CI 1.611-7.038, P = 0.022).